Valuation: Sprint Bioscience AB

Market Cap 386M 39.86M 34.94M 32.3M 29.7M 56.05M 3.84B 56.95M 151M 1.88B 150M 146M 6.48B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 386M 39.86M 34.94M 32.3M 29.7M 56.05M 3.84B 56.95M 151M 1.88B 150M 146M 6.48B EV / Sales 2026 *
4.55x
EV / Sales 2027 * 2.49x
Free-Float
64.78%
Yield 2026 *
-
Yield 2027 * -
1 day-3.28%
1 week-7.57%
Current month-14.49%
1 month-16.71%
3 months+7.93%
6 months+136.79%
Current year+140.82%
1 week 3.5
Extreme 3.5
3.89
1 month 3.5
Extreme 3.5
4.59
Current year 1.36
Extreme 1.355
4.59
1 year 0.5
Extreme 0.5
4.59
3 years 0.36
Extreme 0.36
4.59
5 years 0.36
Extreme 0.36
9.36
10 years 0.36
Extreme 0.36
41.9
Manager TitleAgeSince
Chief Executive Officer 42 01/10/2023
Chief Tech/Sci/R&D Officer 55 01/01/2009
Director of Finance/CFO 55 04/05/2026
Director TitleAgeSince
Chairman 70 01/01/2010
Director/Board Member 50 01/01/2019
Chairman 58 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
-3.28%-7.57%+586.05%+580.77% 40.07M
+0.21%-0.79%+56.02%+57.39% 53.83B
+5.37%+0.75%+50.39%+83.03% 52.1B
-0.18%-0.62%+5.53%+409.46% 23.48B
+0.43%+2.20%-15.48%-14.55% 23.13B
+3.46%+0.79%+34.01%-4.47% 19.36B
-1.18%-2.97%+32.73%-33.30% 17.56B
-1.67%-8.56%+163.95%+284.69% 15.2B
+3.62%-2.42%+29.70%+663.64% 14.83B
+0.10%+0.36%+27.07%+183.04% 14.06B
Average +0.81%-2.71%+97.00%+220.97% 23.36B
Weighted average by Cap. +1.70%-2.35%+42.74%+140.36%

Financials

2026 *2027 *
Net sales 84.8M 8.75M 7.67M 7.09M 6.52M 12.31M 844M 12.5M 33.24M 413M 32.87M 32.15M 1.42B 155M 16M 14.02M 12.96M 11.92M 22.49M 1.54B 22.86M 60.76M 755M 60.08M 58.77M 2.6B
Net income - -
Net Debt - -
Logo Sprint Bioscience AB
Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
Employees
30
Date Price Change Volume
21/07/26 SEK 3.540 -3.28% 103,404
17/07/26 SEK 3.660 -1.61% 138,947
16/07/26 SEK 3.720 +1.64% 193,962
15/07/26 SEK 3.660 -4.69% 245,551
14/07/26 SEK 3.840 +0.26% 67,770

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRINT Stock